ISPOR Patient Representative Travel Grant

The candidate for the Patient Travel Grant must:

• Represent a nonprofit, voluntary health agency [501(c)3 in the US] with a mission to:
  • Combat a particular disease, disability, or group of diseases/disabilities or
  • Improve and protect the health of a particular group of people
• Engage in programs, such as, research, education, advocacy, and service to individuals and communities
• Able to provide patient perspectives relevant to health policy, health technology assessment, and/or research and development (ie clinical trials, therapy development, etc.)
• NOT be employed by health technology producers (biopharmaceutical, medical device, or diagnostic companies)

View Upcoming Conferences

The application for the ISPOR Europe 2024 Travel Grant will open in Summer 2024. 

The recipient of the ISPOR Travel Grant receives complimentary registration to the conference and a fixed-amount travel reimbursement, per the ISPOR Travel Reimbursement Policy. 

The ISPOR Travel Grant application for ISPOR Europe 2024 will open in Summer 2024.

• Ryan Fischer, Foundation for Angelman Syndrome Therapeutics (FAST), United States
• Kate Avery, Beyond Celiac, United States
• Olufunke Akiyode, Shout Global Health, United States
• Ella Balasa, Patient Advocate  , United States
• Tiffany Westrich-Robertson, AiArthritis (International Foundation Autoimmune & Autoinflammatory Arthritis), United States
• Kimberly Richardson, Black Cancer Collaborative, United States
• Ushma Patel, Patient Advocate, United States
• Stephanie Steele, Immune Deficiency Foundatino, United States
• Gail Attara, Gastrointestinal Society, Canada
• Alma Robles Avila, Guatemalan Association of Heroes of Hope for Cancer Patients, Guatemala
• Angie Botto-van Bemden, Musculoskeletal Research International, United States
• Veronica Stasiak Bednarczuk de Oliveira, Unidos pela Vida - Brazilian Institute of Cystic Fibrosis Care, Brazil
• Marjorie Morrison, Lymphoma Coalition, Canada
• Jason Harris, National Psoriasis Foundation, United States
• Kevin Wake, Uriel E. Owens Sickle Cell Disease Association of the Midwest, United States

• Omar A. Escontrias, National Health Council, United States
  
• Birgitta Termander, Rare Diseases Sweden, Sweden
  
• Stavros Terzakis, Union of Heart Patients of Navy Officers, Coast Guard and Friends, Hellenic Navy, Greece
  
• Ana-Ecaterina Amariutei, European Patient Advocacy Institute, Germany 
  
• Richard Ballerand, European Institute for Innovation and Technology, United Kingdom
  
• Jennifer Camaradou, Health ClusterNET, Netherlands 
• Marjorie Morrison, Lymphoma Coalition, Canada 

• Lisa Machado, Canadian CML Network, Canada
  
• Sneha Dave, Generation Patient, United States
  
• Jason Harris, National Psoriasis Foundation, United States
  
• Ashley Valentine, Sick Cells, United States
  
• Kevin Wake, Uriel E. Owens Sickle Cell Disease Association of the Midwest, United States
  
• Anna Hyde, Arthritis Foundation, United States

• Valentina Strammiello, European Patients Forum, Belgium
  
• Stefan Živković, National Organisation for Rare Diseases of Serbia, Serbia
  
• Ananda Plate, Myeloma Patients Europe, Germany
  
• Tina Mesarič, University of Maribor, Slovenia
  
• Merce Cases, European Patient Advocacy Institute, Germany
  
• Sara Pérez Martínez, Freelance Patient Advocate, Spain
  
• Laura Gumbert, SMA Europe, Bayreuth, Germany
  
• Sara Loud, Accelerated Cure Project, Inc., United States
  
• Veronica del Gragnano Stasiak Bednarczuk de Oliveira, Unidos pela Vida-Brazilian Institute of Cystic Fibrosis Care, Brazil
  
• Anne-Pierre Pickaert, Care 4 Access, France
  
• Angie Botto-van Bemden, Musculoskeletal Research International Patient Advocate, United States
  
• Karla Ruiz de Castilla, Esperantra, Peru

• Sita Ratna Devi Duddi, Patient Academy for Innovation and Research, India
• Ellos Lodzeni, International Alliance of Patients'​ Organizations (IAPO), Malawi
• Charlotte Martin, Leukemia Care, United Kingdom
• Derick Mitchell, The Irish Platform for Patient Organisations, Science and Industry (IPPOSI), Ireland
• Silene ten Seldam, Myeloma Patients Europe (MPE), Belgium